S&P 500   3,306.71 (-1.50%)
DOW   27,565.36 (-1.21%)
QQQ   263.71 (-2.45%)
AAPL   106.53 (-3.45%)
MSFT   197.04 (-2.89%)
FB   251.40 (-1.34%)
GOOGL   1,436.75 (-3.38%)
AMZN   2,918.59 (-3.00%)
NVDA   481.50 (-3.42%)
TSLA   434.42 (+2.60%)
BABA   272.06 (-1.33%)
CGC   16.21 (-1.16%)
GE   6.91 (-1.99%)
MU   50.27 (-1.39%)
AMD   74.30 (-2.94%)
T   28.96 (-0.38%)
F   7.24 (-0.55%)
ACB   6.41 (-6.97%)
GILD   64.22 (-1.26%)
NFLX   460.39 (-2.09%)
DIS   128.65 (-1.21%)
BAC   25.28 (-0.28%)
BA   162.35 (-3.09%)
S&P 500   3,306.71 (-1.50%)
DOW   27,565.36 (-1.21%)
QQQ   263.71 (-2.45%)
AAPL   106.53 (-3.45%)
MSFT   197.04 (-2.89%)
FB   251.40 (-1.34%)
GOOGL   1,436.75 (-3.38%)
AMZN   2,918.59 (-3.00%)
NVDA   481.50 (-3.42%)
TSLA   434.42 (+2.60%)
BABA   272.06 (-1.33%)
CGC   16.21 (-1.16%)
GE   6.91 (-1.99%)
MU   50.27 (-1.39%)
AMD   74.30 (-2.94%)
T   28.96 (-0.38%)
F   7.24 (-0.55%)
ACB   6.41 (-6.97%)
GILD   64.22 (-1.26%)
NFLX   460.39 (-2.09%)
DIS   128.65 (-1.21%)
BAC   25.28 (-0.28%)
BA   162.35 (-3.09%)
S&P 500   3,306.71 (-1.50%)
DOW   27,565.36 (-1.21%)
QQQ   263.71 (-2.45%)
AAPL   106.53 (-3.45%)
MSFT   197.04 (-2.89%)
FB   251.40 (-1.34%)
GOOGL   1,436.75 (-3.38%)
AMZN   2,918.59 (-3.00%)
NVDA   481.50 (-3.42%)
TSLA   434.42 (+2.60%)
BABA   272.06 (-1.33%)
CGC   16.21 (-1.16%)
GE   6.91 (-1.99%)
MU   50.27 (-1.39%)
AMD   74.30 (-2.94%)
T   28.96 (-0.38%)
F   7.24 (-0.55%)
ACB   6.41 (-6.97%)
GILD   64.22 (-1.26%)
NFLX   460.39 (-2.09%)
DIS   128.65 (-1.21%)
BAC   25.28 (-0.28%)
BA   162.35 (-3.09%)
S&P 500   3,306.71 (-1.50%)
DOW   27,565.36 (-1.21%)
QQQ   263.71 (-2.45%)
AAPL   106.53 (-3.45%)
MSFT   197.04 (-2.89%)
FB   251.40 (-1.34%)
GOOGL   1,436.75 (-3.38%)
AMZN   2,918.59 (-3.00%)
NVDA   481.50 (-3.42%)
TSLA   434.42 (+2.60%)
BABA   272.06 (-1.33%)
CGC   16.21 (-1.16%)
GE   6.91 (-1.99%)
MU   50.27 (-1.39%)
AMD   74.30 (-2.94%)
T   28.96 (-0.38%)
F   7.24 (-0.55%)
ACB   6.41 (-6.97%)
GILD   64.22 (-1.26%)
NFLX   460.39 (-2.09%)
DIS   128.65 (-1.21%)
BAC   25.28 (-0.28%)
BA   162.35 (-3.09%)
Log in
NASDAQ:FGEN

FibroGen Stock Forecast, Price & News

$43.63
-0.23 (-0.52 %)
(As of 09/18/2020 01:39 PM ET)
Add
Compare
Today's Range
$43.32
Now: $43.63
$44.27
50-Day Range
$40.47
MA: $42.99
$45.37
52-Week Range
$22.65
Now: $43.63
$51.56
Volume8,585 shs
Average Volume697,948 shs
Market Capitalization$3.94 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.63
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. The company is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Duchenne muscular dystrophy; and FG-5200, a corneal implant medical device for the treatment of corneal blindness resulting from partial thickness corneal damage. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was incorporated in 1993 and is headquartered in San Francisco, California.
Read More
FibroGen logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.49 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:FGEN
CUSIPN/A
Phone415-978-1200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$256.58 million
Book Value$6.14 per share

Profitability

Net Income$-76,970,000.00
Net Margins-287.01%

Miscellaneous

Employees461
Market Cap$3.94 billion
Next Earnings Date11/9/2020 (Estimated)
OptionableOptionable
$43.63
-0.23 (-0.52 %)
(As of 09/18/2020 01:39 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive FGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for FGEN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











FibroGen (NASDAQ:FGEN) Frequently Asked Questions

How has FibroGen's stock price been impacted by Coronavirus (COVID-19)?

FibroGen's stock was trading at $35.40 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, FGEN stock has increased by 24.0% and is now trading at $43.90.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of FibroGen?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for FibroGen in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for FibroGen
.

When is FibroGen's next earnings date?

FibroGen is scheduled to release its next quarterly earnings announcement on Monday, November 9th 2020.
View our earnings forecast for FibroGen
.

How were FibroGen's earnings last quarter?

FibroGen Inc (NASDAQ:FGEN) issued its earnings results on Thursday, August, 6th. The biopharmaceutical company reported ($0.95) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.64) by $0.31. The biopharmaceutical company earned $42.90 million during the quarter, compared to analysts' expectations of $48.29 million. FibroGen had a negative net margin of 287.01% and a negative return on equity of 60.97%. FibroGen's revenue was down 77.6% compared to the same quarter last year. During the same period last year, the firm posted $1.26 earnings per share.
View FibroGen's earnings history
.

What price target have analysts set for FGEN?

5 equities research analysts have issued 12 month price targets for FibroGen's shares. Their forecasts range from $40.00 to $90.00. On average, they anticipate FibroGen's stock price to reach $59.60 in the next year. This suggests a possible upside of 35.8% from the stock's current price.
View analysts' price targets for FibroGen
.

Who are some of FibroGen's key competitors?

What other stocks do shareholders of FibroGen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other FibroGen investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Aegean Marine Petroleum Network (ANW), NIC (EGOV), Gran Tierra Energy (GTE), Allergan (AGN) and ALJ Regional (ALJJ).

Who are FibroGen's key executives?

FibroGen's management team includes the following people:
  • Mr. Thomas B. Neff, Founder, Chairman & CEO (Age 65)
  • Mr. Pat Cotroneo, Sr. VP of Fin. & CFO (Age 55)
  • Dr. K. Peony Yu, Chief Medical Officer (Age 57)
  • Mr. Julian N. Stern, Sec. (Age 94)
  • Dr. Barry A. Berkowitz, Founder

When did FibroGen IPO?

(FGEN) raised $146 million in an initial public offering (IPO) on Friday, November 14th 2014. The company issued 8,100,000 shares at $18.00 per share. Goldman Sachs, Citigroup and Leerink Partners acted as the underwriters for the IPO and RBC Capital Markets, Stifel and William Blair were co-managers.

What is FibroGen's stock symbol?

FibroGen trades on the NASDAQ under the ticker symbol "FGEN."

Who are FibroGen's major shareholders?

FibroGen's stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (8.35%), FMR LLC (7.10%), First Trust Advisors LP (1.89%), Bank of New York Mellon Corp (1.67%), Goldman Sachs Group Inc. (1.21%) and Charles Schwab Investment Management Inc. (0.88%). Company insiders that own FibroGen stock include Christine Chung, Elias Kouchakji, Enrique A Conterno, James A Schoeneck, K Peony Yu, Kalevi Kurkijarvi, Pat Cotroneo, Roberto Pedro Rosenkranz, Thomas B Neff and Thomas F Kearns Jr.
View institutional ownership trends for FibroGen
.

Which major investors are selling FibroGen stock?

FGEN stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Artal Group S.A., Rhenman & Partners Asset Management AB, UBS Group AG, Prudential Financial Inc., Barclays PLC, Nuveen Asset Management LLC, and Alps Advisors Inc.. Company insiders that have sold FibroGen company stock in the last year include Christine Chung, K Peony Yu, Kalevi Kurkijarvi, Pat Cotroneo, and Thomas F Kearns Jr.
View insider buying and selling activity for FibroGen
.

Which major investors are buying FibroGen stock?

FGEN stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Bank of New York Mellon Corp, First Trust Advisors LP, Sei Investments Co., Principal Financial Group Inc., Principal Financial Group Inc., Man Group plc, and Hudson Bay Capital Management LP.
View insider buying and selling activity for FibroGen
.

How do I buy shares of FibroGen?

Shares of FGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is FibroGen's stock price today?

One share of FGEN stock can currently be purchased for approximately $43.90.

How big of a company is FibroGen?

FibroGen has a market capitalization of $3.97 billion and generates $256.58 million in revenue each year. The biopharmaceutical company earns $-76,970,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis. FibroGen employs 461 workers across the globe.

What is FibroGen's official website?

The official website for FibroGen is www.fibrogen.com.

How can I contact FibroGen?

FibroGen's mailing address is 409 ILLINOIS STREET, SAN FRANCISCO CA, 94158. The biopharmaceutical company can be reached via phone at 415-978-1200 or via email at [email protected]

This page was last updated on 9/18/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.